Pharmaceutical company Novo Nordisk has presented data at a congress of the American Heart Association confirming the positive effects of the weight-loss drug Wegovy in preventing heart attacks and other severe cardiovascular diseases.
Back in August, the company announced that compared to standard treatment, Wegovy reduces the risk of cardiovascular complications by one-fifth.
The study details presented now show that treatment with a dosage of 2.4 milligrams of Wegovy reduces the risk of the disease regardless of age, gender, ethnicity, or baseline body mass index.
The medication quickly demonstrates its positive effect.
Novo Nordisk has submitted approval applications for Wegovy as a preventive treatment for cardiovascular diseases in the US and the EU, decisions on which will be made in 2024.
Experts are impressed by the data and see a justified use of the medication against cardiovascular diseases. However, capturing the costs by insurers could be challenging, and the price of the medication may need to be adjusted.
Novo Nordisk’s stock price has risen significantly this year, and the company currently has the highest market capitalization in the Stoxx 50 Europe.
„Zombie-Enthusiast. Internet-Liebhaber. Wegbereiter für böses Essen. Freundlicher Bier-Evangelist.“